V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10465735 | 10069317 | 1.8 | 67.5 | null | 2020-08-09 | 2021-03-24 | IGEV | 02 | null | RALTITREXED | 101320526 |
| 10465757 | 10069318 | 1.68 | 63 | null | 2020-04-19 | 2020-05-12 | FLAIR trial | null | null | PEMETREXED | 101283390 |
| 10465984 | 10069319 | 1.81 | 66.8 | Palliative (P) | 2019-05-28 | 2019-06-01 | ELOQUENT 2 trial | 2 | N | LENALIDOMIDE + RITUXIMAB | 100719306 |
| 10466178 | 10069320 | 1.82 | 72.1 | Curative (C) | 2018-02-02 | 2018-05-09 | BEACOPP | 02 | N | ROSCO TRIAL | 101557693 |
| 10466578 | 10069322 | null | null | 03 | 2018-06-24 | 2018-06-28 | VISMODEGIB | 02 | N | LETROZOLE + PALBOCICLIB | 100674194 |
| 10467132 | 10069324 | 1.78 | 93.7 | null | 2020-06-22 | 2020-06-24 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | null | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 100879248 |
| 10467214 | 10069326 | 1.84 | 75 | Curative (C) | 2021-11-01 | 2021-11-28 | MPV (cycle 1-4) | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 101200479 |
| 10467904 | 10069328 | 1.54 | 70.65 | Disease modification (D) | null | 2019-11-19 | null | 02 | N | PENTOSTATIN + RITUXIMAB | 101058072 |
| 10468761 | 10069329 | 0 | 86.5 | null | 2017-12-13 | 2018-11-23 | MYELOMA XI TRIAL | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 100421318 |
| 10468857 | 10069330 | 1.7 | 81.2 | null | 2020-01-15 | 2020-01-15 | Cisplatin + Fluorouracil + RT 5day | 02 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101815249 |
| 10468917 | 10069331 | 1.83 | 88.3 | null | 2017-07-26 | 2019-03-17 | Cytarabine Low Dose | 02 | null | CISPLATIN + PEMETREXED | 101316497 |
| 10468967 | 10069332 | 1.69 | 84.7 | Palliative (P) | 2019-04-11 | 2019-04-15 | ALL UKALL60+ TRIAL | 02 | N | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 100902118 |
| 10469564 | 10069333 | 1.68 | 63.6 | Adjuvant (A) | 2022-04-13 | 2022-04-23 | FLUOROURACIL + IRINOTECAN | 02 | N | DOXORUBICIN | 100168725 |
| 10469587 | 10069334 | 1.52 | 80 | 03 | 2017-09-15 | 2017-10-01 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | CYTARABINE | 100853661 |
| 10469694 | 10069335 | null | null | null | null | 2018-09-15 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | GEMTUZUMAB OZOGAMICIN | 101595280 |
| 10469699 | 10069336 | 1.58 | 72.4 | null | 2020-08-20 | 2021-03-03 | Brentuximab | 01 | null | RUCAPARIB | 101325936 |
| 10470026 | 10069337 | 1.54 | 45.3 | Palliative (P) | null | 2020-09-28 | Capecitabine (21days) + Carboplatin | 02 | N | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 100238493 |
| 10470896 | 10069341 | 1.65 | 61.2 | 03 | 2021-05-27 | 2021-05-28 | null | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 101400672 |
| 10471432 | 10069344 | null | null | null | 2019-11-07 | 2019-11-07 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | DASATINIB | 101558510 |
| 10472609 | 10069346 | 1.59 | 58.6 | Palliative (P) | 2021-02-01 | 2021-10-30 | Asciminib | N | N | FEDRATINIB | 100886658 |
| 10472643 | 10069347 | 1.82 | 61.5 | null | null | 2020-12-28 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE + RITUXIMAB | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100471881 |
| 10472673 | 10069348 | null | null | null | null | 2020-09-25 | BENDAMUSTINE + THALIDOMIDE | 02 | N | GEMCITABINE + OXALIPLATIN | 101243986 |
| 10472697 | 10069349 | null | null | null | 2020-11-14 | 2020-11-28 | CAPECITABINE + MITOMYCIN + RT | 02 | null | IFOSFAMIDE + GEMCITABINE + VINORELBINE | 100903333 |
| 10473777 | 10069352 | 1.71 | 82.7 | Palliative (P) | 2017-10-27 | 2022-05-14 | Cladribine + Rituximab | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 101465874 |
| 10473818 | 10069353 | 0 | 67.3 | null | 2019-10-16 | 2019-10-28 | Bevacizumab 7.5mg/kg | null | null | ERLOTINIB | 101654071 |
| 10474518 | 10069356 | 0 | 0 | Palliative (P) | 2019-06-06 | 2019-06-14 | R GCVP | 02 | N | SORAFENIB | 100491764 |
| 10474622 | 10069357 | 1.71 | 77 | Palliative (P) | 2018-10-31 | 2018-10-31 | BLINATUMOMAB | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101012081 |
| 10476546 | 10069360 | 1.72 | 78.6 | null | 2017-11-18 | 2017-11-19 | PEMBROLIZUMAB + PEMETREXED | 02 | null | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 101634362 |
| 10476699 | 10069361 | null | null | null | 2021-03-30 | 2021-04-05 | Bevacizumab + Olaparib | null | null | DOCETAXEL + TRASTUZUMAB | 101630583 |
| 10477187 | 10069364 | 1.81 | 83.7 | null | 2017-10-11 | 2017-10-20 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | null | FLUOROURACIL + MITOMYCIN | 101650732 |
| 10477608 | 10069365 | 1.7 | 60 | Curative (C) | 2019-12-25 | 2019-12-25 | Obinutuzumab | 02 | N | AZACITIDINE + VENETOCLAX | 100258500 |
| 10477696 | 10069366 | null | 75 | null | 2021-07-01 | 2021-09-05 | GemCarbo Days 1+8 | 02 | null | RUCAPARIB | 101247612 |
| 10477994 | 10069367 | 1.8 | 0 | null | 2022-01-20 | 2022-01-21 | AZACITIDINE + VENETOCLAX | 02 | null | CISPLATIN + PEMETREXED | 101443972 |
| 10479339 | 10069372 | 1.55 | 84.8 | null | 2018-11-04 | 2018-11-19 | ALL UKALL60+ TRIAL | 02 | null | EPIRUBICIN | 100786757 |
| 10479451 | 10069373 | 1.88 | 0 | null | 2020-07-11 | 2020-08-09 | BENDAMUSTINE + Brentuximab Vendotin | 02 | null | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 100627546 |
| 10480204 | 10069375 | 1.64 | 67.5 | null | 2020-06-30 | 2020-07-01 | null | 99 | N | FULVESTRANT + RIBOCICLIB | 101850637 |
| 10480458 | 10069377 | 1.59 | 56 | null | 2018-07-20 | 2018-07-27 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | N | FULVESTRANT + RIBOCICLIB | 101221005 |
| 10480650 | 10069378 | 1.59 | 59.9 | Palliative (P) | 2020-07-25 | 2020-07-30 | ATG + Busulfan + Fludarabine | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101161113 |
| 10481585 | 10069381 | 1.8 | 93.4 | null | 2019-08-06 | 2019-08-06 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | 02 | null | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 101268677 |
| 10001902 | 10069383 | 1.66 | 65.9 | Disease modification (D) | 2021-12-25 | 2021-12-25 | R GCVP | 02 | null | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 101754306 |
| 10025690 | 10069386 | 1.58 | 80.65 | null | 2021-08-15 | 2021-09-03 | CARBO + FLUOROURACIL | 02 | null | BINIMETINIB + ENCORAFENIB | 100195169 |
| 10040757 | 10069387 | 1.8 | 82 | Palliative (P) | 2015-10-09 | 2015-10-09 | RITUXIMAB + prednisolone + VINBLASTINE + prednisolone | 02 | null | VISMODEGIB | 101688093 |
| 10057843 | 10069388 | 1.67 | 73 | Curative (C) | 2020-04-15 | 2020-06-24 | Cyclophosphamide + Dex + Rituximab | null | Y | OLAPARIB | 101687648 |
| 10068099 | 10069390 | 0 | 0 | Adjuvant (A) | null | 2019-06-25 | PERSEPHONE TRIAL | N | Y | CTD | 100901461 |
| 10100529 | 10069392 | 1.63 | 83.6 | null | 2022-01-18 | 2022-01-18 | Apalutamide | 02 | null | EVEROLIMUS | 101475996 |
| 10104573 | 10069393 | 1.69 | 60 | Adjuvant (A) | 2019-01-22 | 2019-01-24 | Carboplatin + Paclitaxel + Pembrolizumab | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100510185 |
| 10115321 | 10069394 | 1.86 | 98.4 | Palliative (P) | 2022-01-31 | 2022-02-06 | VISMODEGIB | 02 | N | BORTEZOMIB + MELPHALAN | 101842694 |
| 10133733 | 10069395 | 1.68 | 48.25 | 03 | 2019-12-23 | 2019-12-23 | Bortezomib + Cyclophos + Dex | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101578948 |
| 10137589 | 10069396 | 1.59 | 76 | Neo-adjuvant (N) | 2020-04-18 | 2020-05-02 | Bexarotene | 02 | N | GEMTUZUMAB OZOGAMICIN | 100966751 |
| 10172452 | 10069401 | 1.78 | 61.1 | null | 2017-07-18 | 2017-07-18 | Nilotinib | 02 | null | VISMODEGIB | 100916754 |